Zentalis Pharmaceuticals (ZNTL) Competitors $1.49 -0.07 (-4.49%) Closing price 10/17/2025 04:00 PM EasternExtended Trading$1.52 +0.02 (+1.68%) As of 10/17/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ZNTL vs. INBX, ATXS, CYRX, SLDB, ALMS, DRUG, LXEO, RAPT, AUTL, and CGEMShould you be buying Zentalis Pharmaceuticals stock or one of its competitors? The main competitors of Zentalis Pharmaceuticals include Inhibrx Biosciences (INBX), Astria Therapeutics (ATXS), CryoPort (CYRX), Solid Biosciences (SLDB), Alumis (ALMS), Bright Minds Biosciences (DRUG), Lexeo Therapeutics (LXEO), Rapt Therapeutics (RAPT), Autolus Therapeutics (AUTL), and Cullinan Therapeutics (CGEM). These companies are all part of the "pharmaceutical products" industry. Zentalis Pharmaceuticals vs. Its Competitors Inhibrx Biosciences Astria Therapeutics CryoPort Solid Biosciences Alumis Bright Minds Biosciences Lexeo Therapeutics Rapt Therapeutics Autolus Therapeutics Cullinan Therapeutics Inhibrx Biosciences (NASDAQ:INBX) and Zentalis Pharmaceuticals (NASDAQ:ZNTL) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, risk, media sentiment, valuation, dividends and profitability. Is INBX or ZNTL more profitable? Zentalis Pharmaceuticals' return on equity of -51.62% beat Inhibrx Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Inhibrx BiosciencesN/A -137.83% -76.31% Zentalis Pharmaceuticals N/A -51.62%-40.28% Which has stronger earnings and valuation, INBX or ZNTL? Inhibrx Biosciences has higher earnings, but lower revenue than Zentalis Pharmaceuticals. Inhibrx Biosciences is trading at a lower price-to-earnings ratio than Zentalis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInhibrx Biosciences$200K2,696.90$1.69B-$10.58-3.52Zentalis Pharmaceuticals$67.43M1.59-$165.84M-$2.26-0.66 Does the media refer more to INBX or ZNTL? In the previous week, Zentalis Pharmaceuticals had 1 more articles in the media than Inhibrx Biosciences. MarketBeat recorded 1 mentions for Zentalis Pharmaceuticals and 0 mentions for Inhibrx Biosciences. Inhibrx Biosciences' average media sentiment score of 0.00 equaled Zentalis Pharmaceuticals'average media sentiment score. Company Overall Sentiment Inhibrx Biosciences Neutral Zentalis Pharmaceuticals Neutral Do insiders & institutionals believe in INBX or ZNTL? 82.5% of Inhibrx Biosciences shares are held by institutional investors. 17.1% of Inhibrx Biosciences shares are held by company insiders. Comparatively, 1.9% of Zentalis Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Which has more volatility and risk, INBX or ZNTL? Inhibrx Biosciences has a beta of 0.51, suggesting that its stock price is 49% less volatile than the S&P 500. Comparatively, Zentalis Pharmaceuticals has a beta of 1.77, suggesting that its stock price is 77% more volatile than the S&P 500. Do analysts rate INBX or ZNTL? Zentalis Pharmaceuticals has a consensus price target of $5.84, suggesting a potential upside of 291.95%. Given Zentalis Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Zentalis Pharmaceuticals is more favorable than Inhibrx Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Inhibrx Biosciences 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50Zentalis Pharmaceuticals 1 Sell rating(s) 3 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.33 SummaryZentalis Pharmaceuticals beats Inhibrx Biosciences on 11 of the 15 factors compared between the two stocks. Get Zentalis Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ZNTL and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ZNTL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ZNTL vs. The Competition Export to ExcelMetricZentalis PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$107.48M$3.44B$6.21B$10.54BDividend YieldN/A2.28%5.70%4.81%P/E Ratio-0.6623.1685.7027.13Price / Sales1.59506.66617.13193.73Price / CashN/A46.9237.1060.81Price / Book0.3210.4112.236.52Net Income-$165.84M-$52.77M$3.33B$276.93M7 Day Performance-11.31%2.31%1.17%1.93%1 Month Performance-1.97%12.59%6.85%2.19%1 Year Performance-52.55%11.18%58.93%34.62% Zentalis Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ZNTLZentalis Pharmaceuticals1.6854 of 5 stars$1.49-4.5%$5.84+291.9%-52.5%$107.48M$67.43M-0.66160INBXInhibrx Biosciences1.6503 of 5 stars$34.38+5.9%N/A+132.8%$470.27M$200K-3.25166ATXSAstria Therapeutics1.9236 of 5 stars$8.47+1.9%$29.50+248.3%+4.5%$468.97MN/A-4.2130Trending NewsAnalyst DowngradeCYRXCryoPort3.2053 of 5 stars$9.40+1.1%$12.56+33.6%+34.0%$465.62M$228.38M7.071,186News CoverageSLDBSolid Biosciences3.0107 of 5 stars$6.01+0.8%$15.00+149.6%-10.9%$464.10M$8.09M-2.15100News CoverageAnalyst DowngradeALMSAlumis3.4371 of 5 stars$4.61+3.8%$20.17+337.5%-62.7%$462.05MN/A0.00N/APositive NewsGap DownDRUGBright Minds Biosciences3.2181 of 5 stars$64.97+2.7%$81.00+24.7%+33.7%$445.81MN/A-69.86N/APositive NewsLXEOLexeo Therapeutics3.0631 of 5 stars$8.20-0.5%$17.00+107.3%-13.8%$444.97M$650K-2.5258Trending NewsAnalyst ForecastInsider TradeRAPTRapt Therapeutics3.1655 of 5 stars$26.35-1.6%$24.78-6.0%+104.9%$443.05M$1.53M-1.8680Analyst RevisionGap UpAUTLAutolus Therapeutics3.5552 of 5 stars$1.65-0.6%$9.12+452.7%-66.3%$441.80M$10.12M-1.96330CGEMCullinan Therapeutics3.5599 of 5 stars$7.83+5.8%$26.00+232.1%-53.1%$437.15MN/A-2.4230News CoveragePositive News Related Companies and Tools Related Companies INBX Competitors ATXS Competitors CYRX Competitors SLDB Competitors ALMS Competitors DRUG Competitors LXEO Competitors RAPT Competitors AUTL Competitors CGEM Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ZNTL) was last updated on 10/19/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredTrump’s new nightmare beginsPorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | Sponsored$15 Fund: Turn Gold Boom into Real IncomeIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zentalis Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Zentalis Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ZNTL Stock Alerts